(Q36929658)

17 August 2017

1 reference

title

The use of hypomethylating agents in the treatment of hematologic malignancies (English)

1 reference

17 August 2017

Jane E Kihslinger

1

1 reference

17 August 2017

Lucy A Godley

series ordinal

2

1 reference

17 August 2017

publication date

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

48

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1676-1695

1 reference

The cancer epigenome--components and functional correlates

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

p53 mutational spectra and the role of methylated CpG sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

DNA methylation and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Treatment of myelodysplastic syndromes with 5-azacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Treatment of acute myelogenous leukemia with outpatient azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

5-Azacytidine in Refractory Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Decitabine--bedside to bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Hypermethylation of gene promoters in hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

DNA hypomethylation and ovarian cancer biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701493910

10.1080/10428190701493910

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference